Monoclonal antibody therapy for genitourinary oncology: Promise for the future

Journal of Urology

Volumn 168, Issue 6, 2002, Pages 2615-2623

  Palapattu, Ganesh S ^a   Reiter, Robert E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies, monoclonal; Antigens; Immunotherapy; Medical oncology; Urology

Indexed keywords

AMINOPTERIN; ANTIGEN G250; CAPROMAB PENDETIDE IN 111; CD20 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN TAG72; HYPOXANTHINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MACROGOL; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MUCIN 1; ONCOFETAL ANTIGEN; ONCOPROTEIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; THYMIDINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANTIGEN BINDING; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG PENETRATION; HUMAN; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY CANCER; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SOLID TUMOR; UROGENITAL TRACT CANCER;

EID: 0036893878     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64230-9     Document Type: Review

References (75)

1. Wright, P. W., Hellstrom, K. E., Hellstrom, I. E. and Bernstein, I. D.: Serotherapy of malignant disease. Med Clin North Am, 60: 607, 1976
2. Green, M. C., Murray, J. L. and Hortobagyi, G. N.: Monoclonal antibody therapy for solid tumors. Cancer Treat Rev, 26: 269, 2000
3. Kohler, G. and Milstein, G.: Continuous culture of fused cells secreting antibody of predefined specificity. Nature, 256: 495, 1975
4. Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W. et al: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res, 40: 3147, 1980
5. Miller, R. A., Maloney, D. G., Warnke, R. and Levy, R.: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med, 306: 517, 1982
6. Goodman, G. E., Hellstrom, I., Brodzinsky, L., Nicaise, C., Kulander, B., Hummel, D. et al: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J Clin Oncol, 8: 1083, 1990
7. Murray, J. L.: Monoclonal antibody treatment of solid tumors: A coming of age. Semin Oncol, Suppl., 27: 64, 2000
8. Zinkernagel, R. M. and Hengartner, H.: Regulation of the immune system by antigen. Rcience, 293: 251, 2001
9. Trauth, B., Klaus, C., Peters, A. M., Matzku, S., Moller, P., Falk, W. et al: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science, 245: 301, 1989
10. Schmolling, J., Reinsberg, J., Wagner, U. and Krebs, D.: Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Hybridoma, 14: 183, 1995
11. Khazaeli, M. B., Conry, R. and LoBuglio, A.: Human immune response to monoclonal antibodies. J Immunol, 15: 42, 1994
12. Boulianne, G., Hozumi, N. and Shulman, M. J.: Production of functional chimaeric mouse/human antibody. Nature, 312: 643, 1984
13. Goodman, G. E., Hellstrom, I., Yeltoni, D. E., Murray, J. L., O'Hara, S., Meaker, E. et al: Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small cell lung, colon, and breast cancer Cancer Immunol Immunother, 36: 267, 1993
14. Riechmann, L., Clark, M., Waldmann, H. and Winter, G.: Reshaping human antibodies for therapy. Nature, 321: 522, 1986
15. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L. et al: Humanization of an anti-p185HER2 anti- body for human cancer therapy. Proc Natl Acad Sci USA, 89: 4285, 1992
16. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E. et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16: 2825, 1998
17. Fan, Z., Masui, H., Altas, I. and Mendelsohn, J.: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res, 53: 4322, 1993
18. Wong, C., Waibel, R., Sheetr, M., Mach, J. and Finnern, R.: Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol Immunother, 50: 93, 2001
19. Todorovska, A., Roovers, R. C., Dolezal, O., Kortt, A. A., Hoogenboom, H. R. and Hudson, P. J.: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Meth, 248: 47, 2001
20. Wu, A. M. and Yazaki, P. J.: Designer genes: Recombinant anti-body fragments for biological imaging. Q J Nucl Med, 44: 268, 2000
21. Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M. et al: A recombinant single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood, 95: 2098, 2000
22. Mueller, B. M., Reisfeld, R. A. and Gillies, S. D.: Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci TSA, 87: 5702, 1990
23. Zuckier, L. S., Berkowitz, E. Z., Sattenberg, R. J., Zhao, Q. H., Deng, H. F. and Scharff, M. D.: Influence of affinity and antigen density on antibody localization in a modified tumor targeting model. Cancer Res, 60: 7008, 2000
24. Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K. et al: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res, 61: 4750, 2001
25. Holliger, P., Wing, M., Pound, J. D., Bohlen, W. and Winter, G.: Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol, 15: 632, 1997
26. Reiter, Y.: Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res, 81: 93, 2001
27. Wilder, R. B., DeNardo, G. L. and DeNardo, S. J.: Radioimmunotherapy: Recent results and future directions. J Clin Oncol, 14: 1383, 1996
28. Garnett, M. C., Embleton, M. J., Jacobs, E. and Baldwin, R. W.: Studies on the mechanism of action of an antibody-targeted drug-carrier conjugate. Anticancer Drug Des, 1: 3, 1985
29. Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J. et al: Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol, 11: 117, 1991
30. McLaughlin, P., Hagemeister, F. B. and Grillo-Lopez, A. J.: Rituximab in indolent lymphoma: The single-agent pivotal trial. Semin Oncol, Suppl., 26: 79, 1999
31. Craft, N., Shostak, Y., Carey, M. and Sawyers, C. L.: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med, 5: 280, 1999
32. Saffran, D. C., Reiter, R. E., Jakobovits, A. and Witte, O. N.: Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev, 18: 437, 1999
33. Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H. G., Kanz, L. et al: Her-2/neu-derived peptides are tumorassociated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res, 58: 732, 1998
34. Rao, J. Y., Hemstreet, G. P., III, Hurst, R. E., Bonner, R. B., Jones, P. L., Min, K. W. et al: Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA, 90: 8287, 1993
35. Orlando, C., Sestini, R., Vona, G., Pinzani, P., Bianchi, S., Giacca, M. et al: Detection of C-ERBB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol, 156: 2089, 1996
36. Miyamoto, H., Kubota, Y., Noguchi, S., Takase, K., Matsuzaki, J., Moriyama, M. et al: C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology, 55: 679, 2000
37. Kollmannsberger, C., Pressler, H., Mayer, F., Kanz, L. and Bokemeyer, C.: Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: Induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol, 10: 1393, 1999
38. Riva, P., Marangolo, M., Tison, V., Moscatelli, G., Franceschi, G., Spinelli, A. et al: Radioimmunotherapy trials in germ testicular carcinoma: A phase I study. Int J Biol Markers, 5: 188, 1990
39. Aaronson, S. A.: Growth factors and cancer. Science, 254: 1146, 1991
40. Reissmann, P. T., Koga, H., Figlin, R. A., Holmes, E. C. and Slamon, D. J.: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol, 125: 61, 1999
41. Prewett, M., Rockwell, P., Rockwell, R. F., Giorgio, N. A., Mendelsohn, J., Scher, H. I. et al: The binlogic effects of C225, a chimerhc monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol, 19: 419, 1996
42. Ye, D., Mendelsohn, J. and Fan, Z.: Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27/Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res, 5: 2171, 1999
43. Slovin, S. F., Kelly, W. K. and Cohen, R.: Epidermal growth factor receptor (EGFR) monoclonal antibody C225 and doxorubicin in androgen-independent prostate cancer: Results of a phase Ib/IIa study. Proc Am Soc Clin Oncol, 16: 311, 1997
44. Perera, A. D., Kleymenova, E. V. and Walker, C. L.: Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res, 6: 1518, 2000
45. Ciardiello, F., Caputo, R., Bhanco, R., Damiano, V., Pomatico, G., Pepe, S. et al: Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst, 90: 1087, 1998
46. Chow, N. H., Liu, H. S., Lee, E. I., Chang, C. J., Chan, S. H., Cheng, H. L. et al: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res, 17: 1293, 1997
47. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J. et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res, 5: 257, 1999
48. Inoue, K., Slaton, J. W., Davis, D. W., Hicklin, D. J., McConkey, D. J., Karashima, T. et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res, 6: 2635, 2000
49. Carter, R. E., Feldman, A. R. and Coyle, J. T.: Prostate-specific membrane antigen is a hydrolase with substrate and pharmocologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA, 93: 749, 1996
50. Texter, J. H., Jr. and Neal, C. E.: The role of monoclonal antibody in the management of prostate adenocarcinoma. J Urol, 160: 2393, 1998
51. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V. et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res, 57: 3629, 1997
52. Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V. et al: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res, 58: 4055, 1998
53. Murphy, G., Tjoa, B., Ragde, H., Kenny, G. and Boynton, A.: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371, 1996
54. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Ragde, H., Rogers, M., Elgamal, A. et al: Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate, 39: 54, 1999
55. Chang, S. S., Reuter, V. E., Heston, W. D. and Gaudin, P. B.: Metastatic renal cell carcinoma neovasculature expresses prostate- specific membrane antigen. Urology, 57: 801, 2001
56. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E. et al: Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA, 95: 1735, 1998
57. Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A. et al: Prostate stem cell antigen (PSCA) exprersion increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene, 19: 1288, 2000
58. Saffran, D. C., Raitano, A. B., Hubert, R. S., Witte, O. N., Reiter, R. E. and Jakobovits, A.: Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA, 98: 2658, 2000
59. Dannull, J., Diener, P. A., Prikler, L., Furstenberger, G., Cerny, T., Schmid, U. et al: Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res, 60: 5522, 2000
60. Amara, N., Palapattu, G. S., Schrage, M., Gu, Z., Thomas, G. V., Dorey, F. et al: Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res, 61: 4660, 2001
61. Hayes, D. F., Mesa-Tejada, R., Papsidero, L. D., Croghan, G. A., Korzun, A. H., Norton, L. et al: Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: A Cancer and Leukemia Group B study. J Clin Oncol, 9: 1113, 1991
62. Zhang, S., Zhang, H. S., Reuter, V. E., Slovin, S. F., Scher, H. I. and Livingston, P. O.: Expression of potential target antigens for immunotherapy of primary and metastatic prostate cancers. Clin Cancer Res, 4: 295, 1998
63. Cardillo, M. R., Castagna, G., Memeo, L., De Bernardinis, E. and Di Silverio, F.: Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer J Exp Clin Cancer Res, 19: 225, 2000
64. Hughes, O. D., Bishop, M. C., Perkins, A. C., Wastie, M. L., Denton, G., Price, M. R. et al: Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol, 18: 363, 2000
65. Paradis, V., Lagha, N. B., Zdiloura, L., Blanchet, P., Eschwege, P., Ba, N. et al: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch, 436: 351, 2000
66. Droller, M. J.: Re: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J Urol, 160: 1932, 1998
67. Vissers, J. L., De Vries, I. J., Schreurs, M. W., Engelen, L. P., Oosterwijk, E., Figdor, C. G. et al: The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res, 59: 5554, 1999
68. Luiten, R. M., Coney, L. R., Fleuren, G. J., Warnaar, S. O. and Litvinov, S. V.: Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer, 74: 735, 1996
69. Steffens, M. G., Boerman, O. C., de Mulder, P. H., Oyen, W. J., Buijs, W. C., Witjes, J. A. et al: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res, Suppl., 5: 3268s, 1999
70. Morris, M. J. and Scher, H. I.: Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer, 89: 1329, 2000
71. Slovin, S. F., Scher, H. I., Divgi, C. R., Reuter, V., Sgouros, G., Moore, M. et al: Interferon-gamma and monoclonal antibody 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res, 4: 643, 1998
72. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H. et al: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med, 35: 1017, 1994
73. Muxi, A., Pons, F., Vidal-Sicart, S., Setoain, F. J., Herranz, R., Novell, R. et al: Radioimmunoguided surgery of colorectal carcinoma with an 111In-labeled anti-TAG72 monoclonal antibody. Nucl Med Commun, 20: 123, 1999
74. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K. et al: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol, 16: 1788, 1998
75. Braun, S., Hepp, F., Kentenich, C. R., Janni, W., Pantel, K., Riethmuller, G. et al: Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res, 5: 3999, 1999